Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Borrebaeck
Carl Borrebaeck, Lund SE
| Patent application number | Description | Published |
|---|---|---|
| 20090285750 | AGENT, COMPOSITION AND METHOD - The present application relates to agents, compositions and methods for use in medicine. In particular, the application relates to an agent comprising a binding moiety capable of selectively binding to Ku protein for use in medicine, in particular in the treatment and diagnosis of cancers. | 11-19-2009 |
Carl Borrebaeck, Hjarup SE
| Patent application number | Description | Published |
|---|---|---|
| 20080248533 | METHOD FOR IN VITRO MOLECULAR EVOLUTION OF PROTEIN FUNCTION - The invention provides a method for generating a polynucleotide sequence or population of sequences from parent single stranded polynucleotide sequences encoding one or more protein motifs, comprising the steps of | 10-09-2008 |
| 20090280526 | Method for in Vitro Molecular Evolution of Protein Function - The invention provides a method for generating a polynucleotide sequence or population of sequences from parent single stranded polynucleotide sequences encoding one or more protein motifs, comprising the steps of | 11-12-2009 |
Carl Arne Krister Borrebaeck, Lund SE
| Patent application number | Description | Published |
|---|---|---|
| 20100105571 | Protein Signature/Markers for the Detection of Adenocarcinoma - The present invention provides a method for determining the presence of pancreatic adenocarcinoma in an individual and/or for determining the survival time of an individual afflicted with pancreatic adenocarcinoma comprising the steps of: (a) providing a serum or plasma sample to be tested; and (b) determining a protein signature of the test sample by measuring the presence and/or amount in the test sample of one or more selected proteins; wherein the presence and/or amount in the test sample of one or more proteins selected from the group defined in Table 1 is indicative of the presence of pancreatic adenocarcinoma. The invention also provides an array and a kit suitable for use in the methods of the invention. | 04-29-2010 |
| 20100119449 | SOX11 EXPRESSION IN MALIGNANT LYMPHOMAS - The present invention provides a binding moiety which selectively binds to Sox11 protein and/or mRNA for imaging, diagnosis or prognosis of lymphomas, such as mantle cell lymphomas (MCL) and diffuse large B-cell lymphoma (DLBCL). Optionally, the moiety is an antibody or antigen-binding fragment thereof. Advantageously, moiety comprises a further, readily detectable moiety. The invention also provides methods of imaging lymphomas cells as well as methods of diagnosing or prognosing lymphomas in an individual. A further aspect of the present invention provides a method of identifying cells associated with lymphomas, the method comprising analysing the pattern of gene expression in a sample of cells to be tested and comparing it to the pattern of gene expression in a sample of known lymphomas cells. Preferably, the cells to be tested are identified as lymphoma cells if the expression of Sox11 is upregulated compared to normal B-cells. | 05-13-2010 |
| 20100304979 | Diagnostic Methods and Arrays for Use in the Same - The present invention provides a method for determining the presence of breast cancer cells in an individual comprising the steps of (a) providing a serum or plasma sample to be tested and (b) determining a protein signature of the test sample by measuring the presence and/or amount in the test sample of two or more proteins selected from the group defined in Table 1a or 1b, wherein the presence and/or amount in the test sample of the two or more proteins selected from the group defined in Table 1a or 1b is indicative of the presence of breast cancer cells. In a preferred embodiment, the two or more proteins include IL-5 and/or MCP-3. Also provided are arrays and diagnostic kits for use in the methods of the invention. | 12-02-2010 |